版本:
中国

BRIEF-VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon

June 1 Vtv Therapeutics Inc

* VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease

* VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease

* VTV Therapeutics - ‍phase 2B results of 5mg per day of azeliragon over period of 18 months showed statistically significant benefit in mild-to-moderate alzheimer's patients​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐